Clarapath has signed a lease for 7,000 square feet at 12 Skyline Drive in Robert Martin’s Mid-Westchester Executive Park in Hawthorne. Clarapath is the developer of an integrated robotics platform designed to standardize and digitally transform anatomic pathology. The company’s fully automated device will act as the eye, hand and brain of a traditional lab technician and provide better quality biopsy slides, faster turnaround times and lower costs for laboratories. The company will utilize the new space for the development and light manufacturing of its technology.
“Covid-19 is accelerating a trend we predicted last year, which is the movement of life sciences and health technologies companies ‘graduating’ out of New York City by expanding into the surrounding suburbs in search of more affordable and flexible spaces,” stated RMC Bio1 Managing Director, Laurence Gottlieb. “Robert Martin Company launched RMC Bio1 last year to take advantage of this emerging trend for the benefit of all Westchester County residents, and I am thrilled the first tenant signed after the launch of this new initiative is a shining example of leading-edge medical technology born and raised in New York State with more to come.”
Clarapath was founded in 2014 as a spin-out from Cold Spring Harbor Laboratory and currently operates at the New York Genome Center in SoHo. The technology being developed, named SectionStar, takes paraffin tissue blocks as inputs and provides glass slides with sliced tissue as outputs. The device is being developed in close concert with Northwell Health, who is also an investor in the company. SectionStar will be transformative toward improving patient care, decreasing costs, and enhancing the quality and consistency of tissue preparation.
“We are extremely excited to make 12 Skyline Drive our new corporate headquarters,” said Eric Feinstein, CEO of Clarapath. “Making this move to Hawthorne will improve efficiency and collaboration, while providing a first-class work environment for our employees. The team at RMC has been wonderful to work with and we look forward to the continued expansion of RMC Bio1 in our facility.”
RMC Bio1 focuses on start-up science and technology companies transitioning from regional incubator and accelerator programs into “graduation” spaces, which are flexible light manufacturing, laboratories and/or offices designed especially for high-growth potential companies utilizing the latest in research and development workflow techniques.
Clarapath is part of RMC Bio1’s redevelopment of 12 Skyline Drive property, which sits within a highly active “innovation district” encompassing New York Medical College and its successful incubator space BioInc@NYMC, Westchester Medical Center and Regeneron Pharmaceuticals’ world headquarters.